Neuropeptide Y Regulation of Bone Metabolism and Homeostasis

Neuropeptide Y (NPY) is a 36-amino-acid peptide abundantly expressed in both the central and peripheral nervous systems. Through multiple G protein-coupled Y receptor subtypes, primarily Y1 and Y2, NPY coordinates systemic energy status with skeletal remodelling. In the hypothalamus, NPY modulates sympathetic outflow to bone, reducing osteoblastic activity under conditions of negative energy balance, whereas locally produced NPY in osteoblasts and osteocytes exerts paracrine control over mesenchymal stem-cell fate and matrix turnover. This bidirectional brain–bone axis enables the skeleton to adapt to metabolic demands but, when dysregulated, contributes to pathological bone loss, age-related marrow adiposity and the coupling of obesity with osteoporosis. Recent work has refined our understanding of receptor-specific actions on osteoblast and osteoclast lineages, revealed cross-talk between NPY pathways and other neurohormonal systems, and highlighted the potential for modulating NPY signalling to enhance bone mass or curb excessive resorption. As metabolic and skeletal disorders become increasingly prevalent, elucidating NPY-driven mechanisms offers promising avenues for therapies that synchronise bone health with energy homeostasis.

Research from Nature Portfolio

Foundational studies have dissected the role of Y1 receptor signalling in osteoclast function. Germline deletion of Y1 receptors in mice provokes the formation of large multinucleated osteoclasts with markedly reduced bone-resorbing activity. Reduced expression of key degradative enzymes such as tartrate-resistant acid phosphatase-5b, matrix metalloproteinase-9 and cathepsin-K underlies the impaired erosion of mineralised matrix. Three-dimensional quantitative analyses of resorption pits revealed substantially decreased surface area, volume and depth. These findings identify Y1 receptor ablation as a novel strategy to attenuate osteoclastic bone loss and inform the development of receptor-targeted interventions for osteoclast-driven diseases.

Neuropeptide Y Regulation of Bone Metabolism and Homeostasis publication trend

The graph below shows the total number of articles in neuropeptide y regulation of bone metabolism and homeostasis across all publications each year (not limited to Nature Index journals).

Technical terms

Neuropeptide Y (NPY): A 36-amino-acid neurotransmitter and hormone that links energy balance with bone remodelling via Y receptor subtypes.

Osteoblast: A bone-forming cell responsible for synthesising and mineralising the organic bone matrix.

Osteoclast: A multinucleated cell that degrades mineralised bone matrix during the resorption phase of bone remodelling.

Y1 receptor: A G protein-coupled receptor for NPY expressed on bone cells and in the central nervous system, mediating inhibitory effects on bone turnover.

Osteocyte: A mature bone cell embedded within the mineralised matrix that senses mechanical load and regulates bone remodelling.

Marrow adipogenesis: The process by which mesenchymal stem cells differentiate into adipocytes within the bone marrow, often at the expense of osteoblast formation.

References

1. Ablation of Y1 receptor impairs osteoclast bone-resorbing activity. Scientific Reports (2016).
2. Neuronal Induction of Bone‐Fat Imbalance through Osteocyte Neuropeptide Y. Advanced Science (2021).
3. The Role of NPY in the Regulation of Bone Metabolism. Frontiers in Endocrinology (2022).
4. Neuropeptide Y Knockout Mice Reveal a Central Role of NPY in the Coordination of Bone Mass to Body Weight. PLOS ONE (2009).